Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors

Next Previous
X
Search
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 Dec 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Baricitinib (Primary)
  • Indications Rheumatoid arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms RA-BEACON
  • Sponsors Eli Lilly and Company; Lilly Korea

    • Most Recent Events

    • 07 Dec 2022 Results from NCT01710358 and NCT01721044 assessing the relative impact of pain and disease activity on improvements in fatigue, published in the JCR: Journal of Clinical Rheumatology
    • 09 Nov 2021 Results assessing effects of Baricitinib on fatigue that are influenced by disease activity and those that are independent of disease activity in patients from the RA-BEAM and RA-BEACON trials, presented at the ACR Convergence 2021
    • 09 Nov 2021 Results of post-hoc analysis of 3 studies (RA-BEGIN (NCT01711359); RA-BEAM (NCT01710358) & RA-BEACON (NCT01721044)) assessing the relative importance of PROs on the Patient Global Assessment of Disease Activity (PtGA) and health-related quality of life (HRQoL) and whether these differ in patients with good disease control compared with those not in low disease activity (LDA) or remission in different patient populations, presented at the ACR Convergence 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top